Non-ionic detergent Tween 80 modulates VP-16 resistance in classical multidrug resistant K562 cells via enhancement of VP-16 influx

Yamazaki, Tetsuo; Sato, Yasushi; Hanai, Masaaki; Mochimaru, Junichiro; Tsujino, Ichiro; Sawada, Umihiko; Horie, Takashi

doi:10.1016/s0304-3835(99)00355-9

Cited by 30 publications

(19 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most efficacious block copolymers exhibited intermediate length of 30–60 PO blocks and a relatively hydrophobic structure (HLB <20; e.g., Pluronic P85 with 40 PO blocks and an HLB of 16). The common mechanisms of surfactants to inhibit P-gp may include binding competition of drugs with surfactants resulting from an interaction between surfactants and P-gp, and membrane fluidization leading to an indirect protein destabilization [108–111]. However, the latter mechanism may not be the case for some surfactants.…”

Section: Drug Delivery Systems To Overcome P-gp-mediated Drug Resistamentioning

confidence: 99%

Nanomedicinal Strategies to Treat Multidrug-Resistant Tumors: Current Progress

2010

View full text Add to dashboard Cite

Multidrug resistance (MDR) is a major impediment to the success of cancer chemotherapy. Pglycoprotein is an important and the best-known membrane transporter involved in MDR. Several strategies have been used to address MDR, especially P-glycoprotein-mediated drug resistance in tumors. However, clinical success has been limited, largely due to issues regarding lack of efficacy and/or safety. Nanoparticles have shown the ability to target tumors based on their unique physical and biological properties. To date, nanoparticles have been investigated primarily to address P-glycoprotein and the observed improved anticancer efficacy suggests that nanomedicinal strategies provide a new opportunity to overcome MDR. This article focuses on nanotechnology-based formulations and current nanomedicine approaches to address MDR in tumors and discusses the proposed mechanisms of action.

show abstract

Section: Drug Delivery Systems To Overcome P-gp-mediated Drug Resistamentioning

confidence: 99%

Nanomedicinal Strategies to Treat Multidrug-Resistant Tumors: Current Progress

2010

View full text Add to dashboard Cite

show abstract

“…Furthermore, due to its extremely low volume of distribution [24,25], delivery of polysorbate 80 outside the central compartment to the tumour is believed to be insignificant, consequently excluding any substantial contribution to cytotoxicity. Polysorbate 80-mediated inhibition of ABCB1 has been observed in vitro [28,29], although not confirmed in vivo [30]. ABCB1, which is expressed in tumours and normal tissues, acts as a drug/xenobiotic efflux pump [27] and its overexpression is implicated in the occurrence of MDR.…”

Section: Introductionmentioning

confidence: 99%

Alternative drug formulations of docetaxel: a review

2007

View full text Add to dashboard Cite

The anticancer drug docetaxel (Taxotere) is formulated in the nonionic surfactant polysorbate 80 (Tween 80). Early in the clinical development of docetaxel, it became clear that docetaxel administration is associated with the occurrence of unpredictable (acute) hypersensitivity reactions and cumulative fluid retention. These side-effects have been attributed, in part, to the presence of polysorbate 80 and have consequently initiated research focused on the development of a less-toxic, better-tolerated polysorbate 80-free formulation of docetaxel. More recently, there is an increasing interest in developing a (polysorbate 80-free) docetaxel formulation that selectively targets malignant tissue, thereby increasing efficacy while decreasing the occurrence of side-effects related to wide and nonspecific body distribution. This review aims to discuss the preclinical and clinical results of pharmaceutical strategies [PEGylated (immuno)liposomal docetaxel, docetaxel-fibrinogen-coated olive oil droplets, docetaxel encapsulated nanoparticle-aptamer bioconjugates, submicronic dispersion formulation] to develop an alternative, solvent-free, delivery form for docetaxel characterized by increased efficacy and decreased toxicity.

show abstract

“…injection and thus seem to mimic lipoprotein particles that are able to interact with members of the low-density lipoprotein receptor family and are taken up via receptor-mediated endorytosis.B ound drugs may be further transported into the brain by diffusion. [62] Another remarkable consideration, which may hinder the development of PBCA Np, is directly connected to the lack of FDA approval both for this polymer and for the surfactant (T-80) required for a good brain targeting result [ 63,64] • Ligand-based approach is related to conjugation with specific ligands (i.e., antibodies, proteins, peptides etc.) able to increase or promote movement across the BBB crossing.…”

Section: International Journal Of Pharmaceutical and Life Sciencesmentioning

confidence: 99%

Drug Delivery to The Brain Using Polymeric Nanoparticles: A Review

Bhatt¹,

Ganesh²,

Kothiyal³

2013

Int. J. Pharma Life Sci.

View full text Add to dashboard Cite

Nanoparticle drug carriers consist of solid biodegradable particles in size ranging from 10 to 1000 nm (50-300 nm generally). The use of minute particles as drug carriers for targeted treatment has been studied over a long period of time. A selective accumulation of active substances in target tissues has been demonstrated for certain so-called nanocarrier systems that are administered bound to pharmaceutical drugs. Great expectations are placed on nanocarrier systems that can overcome natural barriers such as the blood-brain barrier (BBB) and transport the medication directly to the desired tissue and thus heal neurological diseases that were formerly incurable. Polymeric Nanoparticle have been shown to be promising carriers for CNS drug delivery due to their potential both in encapsulating drugs, hence protecting them from excretion and metabolism, and in delivering active agents across the blood -brain barrier without inflicting any damage to the barrier. Different polymers have been used and different strategies like surface modification have been done to increase the retention time of nanoparticles.

show abstract

Non-ionic detergent Tween 80 modulates VP-16 resistance in classical multidrug resistant K562 cells via enhancement of VP-16 influx

Cited by 30 publications

References 9 publications

Nanomedicinal Strategies to Treat Multidrug-Resistant Tumors: Current Progress

Nanomedicinal Strategies to Treat Multidrug-Resistant Tumors: Current Progress

Alternative drug formulations of docetaxel: a review

Drug Delivery to The Brain Using Polymeric Nanoparticles: A Review

Contact Info

Product

Resources

About